REGENXBIO 将参加 Stifel 2026 医疗健康大会
REGENXBIO to Participate in Stifel 2026 Healthcare Conference
REGENXBIO（Nasdaq: RGNX）宣布将参加 Stifel 2026 医疗健康大会，炉边谈话定于 2026 年 11 月 11 日美东时间上午 9:20 在纽约举行，官网投资者栏目提供直播，回放约保留 30 天。
, /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the Stifel 2026 Healthcare Conference.
Fireside Chat Details
Date and Time: Wednesday, November 11, 2026 at 9:20 a.m. ET
Location: New York, NY
A live webcast of the fireside chat can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcasts will be available for approximately 30 days following the event.
ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA® and ITVISMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.
Contacts:
Dana Cormack
Corporate Communications
[email protected]
Investors:
George E. MacDougall
Investor Relations
[email protected]
SOURCE REGENXBIO Inc.
来源：PR Newswire Health · prnewswire.com